Challenges and advances in the assessment of the disposition of antibody-drug conjugates

Biopharmaceutics and Drug Disposition

Volumn 37, Issue 2, 2016, Pages 66-74

  Kamath, Amrita V ^a   Iyer, Suhasini ^a  

^a GENENTECH INC   (United States)

Author keywords

antibody drug conjugate; biotherapeutics; cancer; pharmacokinetics; preclinical

Indexed keywords

ANTIBODY CONJUGATE; CYTOTOXIC AGENT; DRUG ANTIBODY; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ANALYTIC METHOD; CANCER PATIENT; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG EFFICACY; HUMAN; PHARMACODYNAMIC PARAMETERS; PHARMACOKINETIC PARAMETERS; REVIEW; ANIMAL;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; HUMANS; IMMUNOCONJUGATES;

EID: 84930607275     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.1957     Document Type: Review

References (43)

1. Sievers EL, Senter PD,. Antibody-drug conjugates in cancer therapy. Annu Rev Med 2013; 64: 15-29.
2. Carter PJ, Senter PD,. Antibody-drug conjugates for cancer therapy. Cancer J 2008; 14 (3): 154-169.
3. Lambert JM,. Drug-conjugated antibodies for the treatment of cancer. Br J Clin Pharmacol 2012; 76 (2): 248-262.
4. Mullard A,. Maturing antibody-drug conjugate pipeline hits 30. Nature Rev Drug Discov 2013; 12: 329-332.
5. Beck A, Reichert JM,. Antibody-drug conjugates: present and future mAbs 2014; 6: 15-17.
6. Lin K, Tibbitts J,. Pharmacokinetic considerations for antibody drug conjugates. Pharm Res 2012; 29: 2354-2366.
7. Erickson HK, Lambert JM,. ADME of antibody-maytansinoid conjugates. AAPS J 2012; 14 (4): 799-805.
8. Flygare JA, Pillow TH, Aristoff P,. Antibody-drug conjugates for the treatment of cancer. Chem Biol Drug Des 2013; 81: 113-121.
9. Erickson HK, Lewis Phillips GD, Leipold DD, et al., The effect of different linkers on target cell catabolism and pharmacokinetics/pharmacodynamics of trastuzumab maytansinoid conjugates. Mol Cancer Ther 2012; 11 (5): 1133-1142.
10. Hamblett KJ, Senter PD, Chace DF, et al., Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin Cancer Res 2004; 10: 7063-7070.
11. Panowski S, Bhakta S, Raab H, Polakis P, Junutula JR,. Site-specific antibody drug conjugates for cancer therapy mAbs 2014; 6 (1): 34-45.
12. Deng R, Jin F, Prabhu S, Iyer S,. Monoclonal antibodies: what are the pharmacokinetic and pharmacodynamics considerations for drug development? Expert Opin Drug Metab Toxicol 2012; 8 (2): 141-160.
13. Lin JH,. Pharmacokinetics of biotech drugs: peptides, proteins and monoclonal antibodies. Curr Drug Metabol 2009; 10: 661-691.
14. Xin Y, Bai S, Damico-Beyer LA, et al., Anti-neuropilin-1 (MNRP1685A): unexpected pharmacokinetic differences across species, from preclinical models to humans. Pharm Res 2012; 29 (9): 2512-2521.
15. Andersen JT, Daba MB, Berntzen G, Michaelsen TE, Sandlie I,. Cross-species binding analyses of mouse and human neonatal Fc receptor show dramatic differences in immunoglobulin G and albumin binding. J Biol Chem 2010; 285: 4826-4836.
16. Adem YT1, Schwarz KA, Duenas E, Patapoff TW, Galush WJ, Esue O,. Auristatin antibody drug conjugate physical instability and the role of drug payload. Bioconjug Chem 2014; 25 (4): 656-664.
17. Leipold DD, Jumbe N, Duggar D, et al,. Trastuzumab-Mc-vc-PAB-MMAF: the effects of the drug:antibody ratio (DAR) on efficacy, toxicity and pharmacokinetics. AACR Annual Meeting 2007, Abstract #1551.
18. Kaur S, Xu K, Saad OM, Dere FC, Carrasco-Triguero M,. Bioanalytical assay strategies for the development of antibody-drug conjugate biotherapeutics. Bioanalysis 2013; 5 (2): 201-226.
19. Gorovits B, Alley SC, Bilic S, et al., Bioanalysis of antibody-drug conjugates: American Association of Pharmaceutical Scientists Antibody-Drug Conjugate Working Group position paper. Bioanalysis 2013; 5 (9): 997-1006.
20. Xu K, Liu L, Saad OM, et al., Characterization of intact antibody-drug conjugates from plasma/serum in vivo by affinity capture capillary liquid chromatography-mass spectrometry. Anal Biochem 2011; 412: 56-66.
21. Xu K, Liu L, Dere R, et al., Characterization of the drug-to-antibody ratio distribution for antibody-drug conjugates in plasma/serum. Bioanalysis 2013; 5 (9): 1057-1071.
22. Hengel SM, Sanderson R, Valliere-Douglass J, Nicholas N, Leiske C, Alley SC,. Measurement of in vivo drug load distribution of cysteine-linked antibody-drug conjugates using microscale liquid chromatography mass spectrometry. Anal Chem 2014; 86 (7): 3420-3425.
23. Boswell CA, Mundo EE, Zhang C, et al., Differential effects of predosing on tumor and tissue uptake of an 111In-labeled anti-TENB2 antibody-drug conjugate. J Nucl Med 2012; 53 (9): 1454-1461.
24. Alley SC, Zhang X, Okeley NM, et al., The pharmacologic basis for antibody-auristatin conjugate activity. J Pharmacol Exp Ther 2009; 330 (3): 932-938.
25. Boswell CA, Mundo EE, Zhang C, et al., Impact of drug conjugation on pharmacokinetics and tissue distribution of anti-STEAP1 antibody-drug conjugates in rats. Bioconjug Chem 2011; 22 (10): 1994-2004.
26. Boswell CA, Bumbaca D, Fielder PJ, Khawli LA,. Compartmental tissue distribution of antibody therapeutics: experimental approaches and interpretations. AAPS J 2012; 14 (3): 612-618.
27. Herbertson RA, Tebbutt NC, Lee FT, et al., Phase I biodistribution and pharmacokinetic study of Lewis Y-targeting immunoconjugate CMD-193 in patients with advanced epithelial cancers. Clin Cancer Res 2009; 15 (21): 6709-6715.
28. Bender B, Leipold DD, Xu K, Shen BQ, Tibbitts J, Friberg LE,. A mechanistic pharmacokinetic model elucidating the disposition of trastuzumab emtansine (T-DM1), an antibody-drug conjugate (ADC) for treatment of metastatic breast cancer. AAPS J 2014; 16 (5): 994-1008.
29. Lu D, Girish S, Gao Y, et al., Population pharmacokinetics of trastuzumab emtansine (T-DM1), a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of covariates. Cancer Chemother Pharmacol 2014; 74 (2): 399-410.
30. Gibiansky L, Gibiansky E,. Target-mediated drug disposition model and its approximations for antibody-drug conjugates. J Pharmacokinet Pharmacodyn 2014; 41 (1): 35-47.
31. Shah DK, Haddish-Berhane N, Betts A,. Bench to bedside translation of antibody drug conjugates using a multiscale mechanistic PK/PD model: a case study with brentuximab-vedotin. J Pharmacokinet Pharmacodyn 2012; 39 (6): 643-659.
32. Deslandes A,. Comparative clinical pharmacokinetics of antibody-drug conjugates in first-in-human Phase 1 studies. MAbs 2014; 6 (4): 859-870.
33. Shen BQ, Bumbaca D, Saad O, et al., Catabolic fate and pharmacokinetic characterization of trastuzumab emtansine (T-DM1): an emphasis on preclinical and clinical catabolism. Curr Drug Metab 2012; 13 (7): 901-910.
34. Poon KA, Flagella K, Beyer J, et al., Preclinical safety profile of trastuzumab emtansine (T-DM1): mechanism of action of its cytotoxic component retained with improved tolerability. Toxicol Appl Pharmacol 2013; 273 (2): 298-313.
35. Krop IE, Beeram M, Modi S, et al., Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J Clin Oncol 2010; 28 (16): 2698-2704.
36. Lewis Phillips GD, Li G, Dugger DL, et al., Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res 2008; 68 (22): 9280-9290.
37. Sun X, Widdison W, Mayo M, et al., Design of antibody-maytansinoid conjugates allows for efficient detoxification via liver metabolism. Bioconjug Chem 2011; 22 (4): 728-735.
38. Younes A, Bartlett NL, Leonard JP, et al., Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010; 363 (19): 1812-1821.
39. Shen BQ, Xu K, Liu L, et al., Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. Nat Biotechnol 2012; 30: 184-189.
40. Strop P1, Liu SH, Dorywalska M, et al., Location matters: site of conjugation modulates stability and pharmacokinetics of antibody drug conjugates. Chem Biol 2013; 20 (2): 161-167.
41. Leal M, Sapra P, Hurvitz SA, et al., Antibody-drug conjugates: an emerging modality for the treatment of cancer. Ann NY Acad Sci 2014; 1321 (1): 41-54.
42. Dowell JA, Korth-Bradley J, Liu H, King SP, Berger MS,. Pharmacokinetics of gemtuzumab ozogamicin, an antibody-targeted chemotherapy agent for the treatment of patients with acute myeloid leukemia in first relapse. J Clin Pharmacol 2001; 41: 1206-1214.
43. Kung Sutherland MS, Walter RB, Jeffrey SC, et al., SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML. Blood 2013; 122 (8): 1455-1463.